Table of Contents
From the Editor
- Lipoprotein ‘little a’: More than a little target in the management of cardiovascular risk?
Lipoprotein(a) was once believed to play no contributory role in the development of cardiovascular disease. That storyline has since flipped.
The Clinical Picture
- Multiple scabietic nodules on the scrotum in a patient living with HIV infection
A 21-year-old man presented with pruritic erythematous papules and nodules on the scrotum and linear keratotic burrows on the right wrist.
1-Minute Consult
- Should we continue guideline-directed medical therapy in patients with heart failure with improved ejection fraction?
Therapy should be continued even if left ventricular ejection fraction improves, as normalization or improvement does not guarantee a permanent recovery.
Editorial
- Rethinking recovery in heart failure: Beyond improvement in left ventricular ejection fraction
The authors discuss 3 unresolved questions about de-escalating and escalating guideline-directed medical therapy in patients with improved ejection fraction.
1-Minute Consult
- What is the optimal time for bone density screening in patients with premature ovarian insufficiency?
Dual-energy x-ray absorptiometry should be performed at diagnosis, with the timing of repeat scans predicated on the patient’s clinical risk factors for fracture.
Review
Lipoprotein(a) in clinical practice: What clinicians need to knowElevated lipoprotein(a) by itself is not an indication for statin therapy, but its presence supports earlier or more aggressive preventive therapy.
- Managing obesity in older adults
The goals of treating obesity in older adults are to ease its complications and improve functional status and quality of life, with or without weight loss.
- Thyroid eye disease: What’s the latest?
A better understanding of the pathophysiology of this autoimmune disorder has led to innovative insights into its treatment, but long-term management remains a challenge.
Editorial
- Teprotumumab for thyroid eye disease: A reality check
Initial enthusiasm for teprotumumab as therapy for thyroid eye disease has been tempered by longitudinal data suggesting that it often does not alter the natural disease course.
Commentary
Failure to thrive documented as an admitting diagnosis presents an opportunity to identify, articulate, and begin to ameliorate the true underlying causes of the patient’s health deficits.